In a major regulatory step to protect patient safety and enhance healthcare accountability, the Indian Pharmacopoeia Commission (IPC) issued a comprehensive national guidance document mandating hospitals to report all serious adverse events related to medical devices within 15 days. Prepared in collaboration with the World Health Organization (WHO) India, the strict new protocol targets a broad spectrum of critical equipment, including insulin pumps, infusion machines, defibrillators, pulse oximeters, diagnostic tools, and AI-enabled medical software. Under the guidelines unveiled by Union Minister Anupriya Patel during National Pharmacovigilance Week, healthcare facilities must submit serious incident reports directly to the Materiovigilance Programme of India (MvPI). Crucially, the protocol enforces reporting for "near-miss" incidents—allowing technical malfunctions or manufacturing flaws detected prior to patient use to be reported within 30 days. To encourage active public participation, the commission also launched a multilingual toll-free helpline enabling patients to report faulty devices directly. Health experts and patient advocacy groups hailed the framework as a crucial upgrade, emphasizing that systematic hospital safety audits and prompt reporting will prevent clinical injuries, improve device standards, and strengthen overall healthcare quality across the country.

National Guidance Framework Strengthens Post-Market Surveillance

In a major initiative to bolster patient safety and clinical accountability, the Indian Pharmacopoeia Commission (IPC)—in collaboration with World Health Organization (WHO) India—issued updated guidelines titled "Guidance Document for Hospitals in India for Safety Monitoring and Reporting of Medical Devices Related Incidents/Adverse Events (Version 1.3)". Unveiled by Union Minister of State for Health and Family Welfare Anupriya Patel during the 6th National Pharmacovigilance Week, the directives establish standardized timelines and active monitoring protocols across primary, secondary, and tertiary healthcare facilities.

Overview: IPC Materiovigilance Programme of India (MvPI) Directives

Regulatory ParameterOfficial Mandate & Standardized Timelines
Formulated GuidelinesGuidance Document for Hospitals in India (Version 1.3)
Serious Adverse Event ReportingWithin 15 Days to MvPI & Licensing Authorities
Non-Serious / Near-Miss ReportingWithin 30 Days
Scope of EquipmentImplants, life-support gear, IVDs, & AI/software medical devices
Active Surveillance RequirementWeekly/monthly monitoring for critical ICU & OT equipment
Public Consumer Toll-Free Line1800-180-3024 (Supported across 10 regional languages)

15-Day and 30-Day Reporting Mandates for Healthcare Facilities

Under the updated reporting framework, hospitals are legally required to report any serious Medical Device Adverse Event (MDAE)—defined as an incident resulting in patient death, severe illness, or significant health deterioration—to the National Coordination Centre of the MvPI within 15 days of occurrence. Suspected unexpected serious adverse events must also be submitted to the relevant licensing authority within the same 15-day window.

For non-serious adverse events, performance failures, design flaws, labeling errors, and pre-use near-misses that carry potential harm risks, healthcare establishments must report details within 30 days. The IPC emphasized that reporting should occur even when a definitive causal link between the medical device and the patient outcome has not yet been established, prioritizing precautionary surveillance over definitive proof.

Hospital Nodal Officers and Direct Consumer Access

To operationalize the directives, hospitals nationwide are instructed to designate departmental nodal officers or establish dedicated Medical Device Adverse Event Monitoring Centres (MDMCs). Intensive care units (ICUs), operation theatres (OTs), and catheterization labs are mandated to maintain active surveillance lists for high-risk equipment—such as infusion pumps, defibrillators, pulse oximeters, and implantable devices—reviewing device performance weekly or monthly.

Beyond institutional reporting via the centralized Adverse Drug Reactions Monitoring System (ADRMS) portal, the IPC established direct channels for patients and consumers. Citizens who experience or observe device malfunctions can report issues directly via a dedicated multilingual toll-free helpline (1800-180-3024) supporting 10 languages.